Adyen Co-CEO Ingo Uytdehaage joins the conversation, discussing Adyen's competitive edge over Stripe. The episode delves into the challenges and strategies for building and scaling a tech company in Europe, with insights into Adyen's expansion into India. Ingo shares thoughts on stablecoins, financial deplatforming, and the role of AI in fintech, including the potential of open-source solutions. The discussion also covers the complexities of offering services in authoritarian countries, leveraging data for economic forecasting, and the dynamics of working as a Co-CEO.

In this episode, David Friedberg introduces a panel focused on the evolving eVTOL industry. The discussion features insights from Joby Aviation, Archer Aviation, and Wisk Aero, highlighting their unique approaches and innovations. Key consumer issues such as liquidity, scalability, and pro-eVTOL regions are examined. The panel delves into autonomous flight technology, redundancy, pilot necessity, and handling edge cases. Acoustic challenges, network creation through scale, marketing strategies, and battery technology are explored. The conversation wraps up with predictions on the commercial availability of eVTOLs and navigating FAA regulations.

David Friedberg engages in a conversation with Eli Lilly CEO Dave Ricks, exploring the global obesity epidemic and the discovery of GLP-1s. They discuss the effects of GLP-1s on various human functions and delve into the commercial aspects of drug discovery, including pricing strategies. The episode addresses criticism and research surrounding GLP-1 dependency, as well as the company's stock performance and political pressures tied to successful drugs. Dave Ricks shares insights on Eli Lilly's diverse drug portfolio beyond GLP-1s and the scientific advancements that excite him. The episode concludes with a discussion on scaling and influencing culture in a company with over a century of history.